Idenix Pharmaceuticals, Inc. Reports Second Quarter and Six Month 2012 Financial Results and HCV Program Update

Published: Aug 09, 2012

CAMBRIDGE, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2012 and provided an update of its hepatitis C virus (HCV) development programs.

Back to news